

**DAVID J. MUZINA, MD**

Former chief resident, psychiatry, Cleveland Clinic. Medical director of inpatient psychiatry, Fairview Lutheran Hospital, Cleveland. His areas of research are social phobia, chemical dependency, and attitudes towards the use of psychostimulants.

DONALD A. MALONE, MD

Director, Mood and Anxiety Disorder Clinic, Cleveland Clinic.

Panic disorder in primary care: A cause of unexplained symptoms

PANIC DISORDER IS COMMON, chronic, and, if unrecognized and untreated, costly. As many as 3.5% of the general population suffers from it at some point in their lives,¹ and the prevalence has been reported to be as high as 11% in general medical patients.^{2,3}

The cost to the patient of unrecognized panic disorder may include other anxiety disorders, depression, drug and alcohol abuse, impaired social and physical functioning, lost workdays and productivity, occupational disability,^{4,5} and even suicide attempts.⁶⁻⁹ The cost to the health care system: increased use of general medical services, frequent clinic and emergency department visits, and excessive testing for organic causes. Fortunately, panic disorder is treatable, and early diagnosis and psychiatric care can significantly reduce the use of nonpsychiatric services.⁵

Many patients with panic disorder present to primary care physicians, but specialists such as emergency room physicians, cardiologists, gastroenterologists, and neurologists should also keep this disorder in mind as a cause of unexplained or persistent physical symptoms in their patients. This review presents the diagnosis and treatment of panic disorder; we also delve into its pathophysiology.

■ DIAGNOSING PANIC DISORDER

Many of the symptoms of panic attacks are physical (**TABLE 1**), making its diagnosis difficult. Further, many patients minimize or deny psychological symptoms. Because of these factors, panic disorder often becomes a diagnosis of exclusion with an extensive differential diag-

■ ABSTRACT:

Patients with panic disorder often believe they are suffering a myocardial infarction or another life-threatening illness. The history and physical examination and a few tests usually suffice to diagnose this disorder, which is treatable with behavioral therapy, antidepressants, and benzodiazepines.

■ KEY POINTS:

Many symptoms of panic attacks are physical, making diagnosis difficult and often suggesting another physical illness.

The etiology of panic likely represents a neurochemical imbalance of serotonin, norepinephrine, and other neurotransmitters.

Treatment consists of a combination of cognitive behavioral therapy, selective serotonin reuptake inhibitors, benzodiazepines, and tricyclic antidepressants. Other agents can be used in refractory cases, but usually require psychiatric referral and evaluation.

TABLE 1

SYMPTOMS OF PANIC ATTACKS

Four of these symptoms are required for the diagnosis of panic attack:

Chest pain or discomfort
Chills or hot flushes
Depersonalization (feeling detached from oneself)
Derealization (feelings of unreality)
Fear of losing control or going crazy
Fear of dying
Feeling dizzy, unsteady, lightheaded, or faint
Feeling of choking
Nausea or abdominal distress
Palpitations, pounding heart, or accelerated heart rate
Paresthesias
Sensations of shortness of breath or smothering
Sweating
Trembling or shaking

SOURCE: ADAPTED FROM THE AMERICAN PSYCHIATRIC ASSOCIATION, REFERENCE 10

TABLE 2

DIFFERENTIAL DIAGNOSIS OF PANIC DISORDER

Atypical migraines
Carcinoid syndrome
Cardiac arrhythmia
Chronic fatigue syndrome
Coronary artery disease
Diabetes mellitus
Drug withdrawal
Hypertension
Hyperthyroidism
Hypoglycemia
Meniere's disease
Partial complex seizures
Pheochromocytoma
Recurrent pulmonary emboli
Substance abuse

SOURCE: ADAPTED FROM WEINSTEIN, REFERENCE 38

nosis (TABLE 2); yet it should be a diagnosis of inclusion, as its symptoms are quite consistent from patient to patient.

Criteria for diagnosing panic disorder

According to criteria from the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* (DSM-IV),¹⁰ panic disorder consists of:

Recurrent panic attacks—acute episodes of severe anxiety accompanied by a variety of somatic symptoms: cardiac, neurologic, gastrointestinal, respiratory, and psychologic (TABLE 1). An attack must include at least four of the symptoms listed in TABLE 1, develop abruptly, and reach a peak intensity within 10 minutes. Panic attacks may be unexpected or occur in response to upsetting circumstances, such as exposure to heights or the sight of blood. Patients usually clearly recall the initial or

“herald” attack even years later. Many patients report episodes of panic starting during sleep.

In addition, the criteria stipulate that patients must have at least one of the following, lasting at least 1 month:

Persistent concern about having additional attacks.

Worry about the implications of the attack or its consequences (eg, losing control, having a heart attack, “going crazy”).

A significant change in behavior related to the attacks.

Repeated panic attacks may lead sufferers to avoid situations that may precipitate attacks or from which getting help or escaping may be difficult. Patients may completely avoid anxiety-provoking situations, endure them with great distress, or require the presence of a companion. Agoraphobia may develop in almost 40% of persons with panic disorder; some patients never leave home, or leave home only with a spouse or family member.¹

Many patients with panic disorder develop agoraphobia

Differential diagnosis

A complete history and physical examination can rule out most of the disorders in the differential diagnosis (TABLE 2); other disorders can be ruled out by routine screening tests such as a complete blood count, thyroid function tests, a fasting glucose level, serum electrolyte levels, and an electrocardiogram.

■ PANIC DISORDER CAN MIMIC OTHER CONDITIONS

Cardiac conditions

Unexplained chest pain, palpitations, or hypertension may precipitate a consultation with a cardiologist. A variety of “functional” cardiac syndromes such as soldier’s heart, neurocirculatory asthenia, hyperdynamic beta-adrenergic circulatory state, and hyperventilation syndrome are likely panic disorder or closely related to it.¹¹ Many patients with these symptoms initially present to the emergency department.

Chest pain. One study found that roughly one in four patients presenting to the emergency department because of chest pain suffered from panic disorder, although chart reviews indicated that 98% of the cases of panic disorder were not recognized as such at the time.¹² Between 20% and 30% of patients who undergo coronary arteriography for chest pain have normal coronary arteries, and in one study, 43% of patients with negative arteriograms were found to have panic disorder.^{13,14}

Labile hypertension. In patients with labile hypertension screened for pheochromocytoma with negative results, psychiatric interviews determined that nearly half had either panic disorder or agoraphobia or both.¹⁵

A link with mitral valve prolapse. Echocardiographic studies have revealed that as many as 40% of patients with panic disorder may also have mitral valve prolapse, but this relationship is of unclear significance.¹⁶

Neurologic conditions

A variety of the symptoms listed in TABLE 1 may prompt a neurologic consultation.

Headache frequently occurs during panic

attacks, although it is not included in the DSM-IV diagnostic criteria. In one study, nearly 28% of people ages 24 to 29 who visited a physician for headache had a history of panic disorder.¹⁷

Epilepsy. Although some features of panic disorder (paroxysmal onset, short duration, psychosensory symptoms, dissociative states) may resemble epilepsy, the relationship between the two is not clear.

Irritable bowel syndrome

Patients with irritable bowel syndrome are frequently referred to gastroenterologists and tend to use a disproportionate amount of medical services.¹⁸ Panic disorder was diagnosed in 28% of irritable bowel syndrome patients, and 41% met the criteria for agoraphobia.¹⁹ Therefore, close screening for anxiety disorders such as panic disorder is warranted as part of any evaluation of a patient with irritable bowel symptoms.

■ EPIDEMIOLOGY

Panic attacks may first appear after a significant life event or stressor, such as the death of a close family member, divorce, or loss of a job. However, they most often afflict people who have no past or recent history of emotional turbulence or traumatic life events. Panic disorder affects 2.5 times more women than men.¹ More than 7% of all people experience a panic attack in their lifetime, and the estimated lifetime prevalence of panic disorder is 3.5%.¹ The prevalence of panic disorder and panic attacks is greatest in persons aged 15 to 24 years; however there is another peak between the ages of 45 and 54.¹ Although panic disorder may develop later in life, the onset of panic attacks after age 60 should increase one’s suspicion of an organic cause (TABLE 2).

Genetics

Panic disorder tends to be familial. One study reported that first-degree relatives of patients with panic disorder had a prevalence of panic disorder of 41%.²⁰ The concordance rate for panic disorder in monozygotic twins has been reported to be five times greater than in dizygotic twins.²¹ In addition, children of patients

The onset of panic attacks after age 60 should increase suspicion of an organic cause

What causes panic disorder?

RESearchers have uncovered certain biological alterations in panic disorder, as in many other psychiatric disorders.

■ NEUROTRANSMITTER IMBALANCES

This disease probably does not result from simple underactivity or overactivity of any one neurotransmitter; rather, there is most likely an imbalance in several neurotransmitter systems that interact in an intricate neural circuit.

Neurotransmitters linked to panic disorder include norepinephrine, serotonin, gamma-aminobutyric acid (GABA), dopamine, and cholecystikinin.¹ Current treatments mostly target norepinephrine and serotonin.

Norepinephrine. Central noradrenergic mechanisms have been identified as a possible pathophysiologic pathway for the development of anxiety and panic. The locus caeruleus, located in the pons, has diffuse ascending projections for noradrenergic transmission to the limbic system and the paralimbic prefrontal and temporal cortex. This system helps process sensory information and, notably, enhances environmental stimuli crucial to survival.² Heightened reactivity of this system may be responsible for anxiety and panic, as suggested by experiments in monkeys in which electrical stimulation of the locus caeruleus produced fear behaviors.³ Further, drugs that produce anxiolysis, such as tricyclic antidepressants, decrease the activity of the locus caeruleus neurons.⁴

Serotonin. A serotonergic pathway originates in the dorsal and median raphe nuclei and ascends to the frontal cortex and limbic system; this pathway, like the noradrenergic system described above, may also heighten sensory perception, participate in interpreting emotionally significant events, and produce fear, anxiety, and panic reactions under dysfunctional states.

The best evidence for serotonin dysfunction

in panic disorder comes from studies in which patients were given direct serotonin agonists or agents that affect serotonin reuptake. One study reported heightened anxiety responses and abnormally elevated cortisol and prolactin responses to fenfluramine, an indirect serotonin agonist.⁵ In addition, selective serotonin reuptake inhibitors are effective in treating anxiety and panic disorder, lending support to the hypothesis of serotonergic dysfunction.

GABA is hypothesized to have a role in the pathophysiology of panic disorder, primarily because benzodiazepines, which act as agonists at the GABA/benzodiazepine receptors, are effective for treating panic attacks.

■ HYPERSENSITIVITY TO CARBON DIOXIDE

Inhalation of 35% CO₂ produces acute anxiety in patients with panic disorder but not in normal controls or patients with other anxiety disorders.⁶ According to a “false suffocation alarm” theory, patients with panic disorder have a genetic impairment of the respiratory control system that makes them hypersensitive to CO₂—ie, “normal” respiratory stimulations produce abnormal responses of a suffocation alarm system, experienced as acute anxiety attacks.⁷

■ REFERENCES

1. Johnson MR, Lydiard RB, Ballenger JC. Panic disorder: pathophysiology and drug treatment. *Drugs* 1995; 49(Suppl 3):328–344.
2. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus caeruleus: new evidence of anatomical and physiological specificity. *Physiol Rev* 1983; 63:844–914.
3. Redmond DE, Huang YH, Snyder DR, et al. Behavioral effects of stimulation of the locus caeruleus in the stump-tail monkey. *Brain Res* 1976; 116:502–510.
4. Krystal JH, Niehoff Deutsch D, Charney DS. The biological basis of panic disorder. *J Clin Psychiatry* 1996; 57(Suppl 10):23–31.
5. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. *Psychiatry Res* 1989; 28:295–306.
6. Verburg K, Griez E, Meijer J, Pols H. Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. *Am J Psychiatry* 1995; 152:1081–1083.
7. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. *Arch Gen Psychiatry* 1993; 50:306–317.

with panic disorder appear to be at increased risk for anxiety disorders and certain temperamental characteristics.²² Separation anxiety in childhood may also lead to panic disorder in adulthood.²³

TREATING PANIC DISORDER

From the outset, patients should receive information about panic disorder; many are relieved to find that their symptoms are not life-threatening or “crazy” and that the disorder may have more of a biological than psychological cause.

Patients should reduce their intake or stop using potentially anxiety-provoking substances such as:

- Caffeine.
- Pseudoephedrine and other decongestants.
- Diet pills.
- Theophylline (if possible).
- Alcohol (although it initially reduces anxiety, its effects wear off quickly, resulting in rebound anxiety and panic symptoms).
- Recreational drugs.

Behavioral therapy

Many mental health professionals favor an initial trial of behavioral therapy before resorting to medications, because this approach is effective and free of side effects. In cognitive-behavioral therapy, patients learn how to reduce panic symptoms through relaxation, diaphragmatic breathing, and other methods. Therapists address the patients’ catastrophic misinterpretation of panic symptoms, such as their beliefs that they may die or that the attacks produce physical harm, and teach them appropriate cognitive interventions.

Some studies have shown behavioral therapy to have both long-term and short-term benefits, particularly in patients who have had a poor response to pharmacotherapy.²⁴ When patients need medications, they tend to need lower doses if they are also undergoing behavioral therapy. They are also more likely to be able to stop taking medications and less likely to have a relapse.^{25,26}

TABLE 3

MEDICATIONS FOR PANIC DISORDER

Drug	Dosage range (mg/day)	
	Initial	Therapeutic
Selective serotonin reuptake inhibitors		
Fluoxetine	5–10	10–60
Sertraline	25–50	50–200
Paroxetine	10–20	20–50
Fluvoxamine	25–50	25–300
Benzodiazepines		
Alprazolam	1–2*	1–8*
Clonazepam	1–2†	1–8†
Lorazepam	1–2†	1–8†
Diazepam	2–10‡	2–40‡

*In divided doses, three to four times a day

†In divided doses, two to three times a day

‡In divided doses, twice a day

Selective serotonin reuptake inhibitors as first-line drugs

Most clinicians favor selective serotonin reuptake inhibitors (SSRIs) as first-line drugs because these agents have a favorable side-effect profile and minimal risk of overdose. Fluoxetine, sertraline, paroxetine, and fluvoxamine have all proved effective in treating panic disorder.^{26–29}

Dosage. SSRIs should be started at very low doses and gradually titrated upwards (TABLE 3). This approach may decrease side effects such as the abnormal stimulation (“activation”) sometimes seen in patients with panic disorder treated with these drugs, and thus increase patient compliance. SSRIs often take at least 2 to 6 weeks to produce an antipanic response, a delay in onset of action similar to that seen in treating depression with these agents.

Benzodiazepines as adjunctive treatment

Some patients with severe panic attacks may also need benzodiazepines, especially patients presenting to the emergency department.

Start SSRIs at very low doses and gradually titrate upward

Benzodiazepines can provide fast relief before the SSRI “kicks in”

Benzodiazepines have the benefit of relieving distressful symptoms faster than do SSRIs. They are also better for treating phobic avoidance. These agents are often effective as monotherapy as well.

Most of the benzodiazepines are effective in treating panic. Highly potent agents such as alprazolam and clonazepam may be better tolerated than less potent agents such as diazepam because they cause less sedation and incoordination.³⁰ Nevertheless, diazepam and alprazolam have been shown to be equally effective.³¹

Cautions. All benzodiazepines can produce physiologic and psychologic dependence, and patients need to be told about this possibility, as well as the danger of a withdrawal syndrome if these drugs are suddenly stopped. Tolerance to benzodiazepines may develop, necessitating an increase in dosage for the drug to remain effective. Long-term use of benzodiazepines may lead to depression, particularly in patients with panic disorder.³² Stopping benzodiazepines may be difficult and requires gradual reduction of dosages to avoid the increase in panic symptoms commonly seen with rapid tapering after long-term use.

Dosage. TABLE 3 lists the dosages of some of the benzodiazepines typically used for managing panic disorder. Although alprazolam, with its rapid onset and short duration of action, can be used “as needed” to stop panic attacks, long-term treatment of panic disorder with benzodiazepines is best managed with regular daily doses. Treatment with shorter-acting benzodiazepines may lead to panic symptoms at night or just before the next scheduled dose of the medication, likely due to a trough concentration effect.

Tricyclic antidepressants

Although no longer used as frequently as SSRIs or benzodiazepines, tricyclic antidepressants are also effective against panic attacks and panic disorder. Imipramine is the prototypical tricyclic antidepressant for panic; its effects are dose-dependent, and plasma levels may assist in individual dosing strategies.³³

Dosage. Treatment with imipramine should start with a low dose (10 mg) at bed-

time and increase to a full antidepressant dose of 150 to 300 mg daily. Adverse effects may limit treatment and include typical anticholinergic side effects such as dryness of mucous membranes, constipation, blurry vision, and urinary retention. Weight gain and sedation can also be troublesome.

Combined treatment

A common approach is to begin treatment with both an antidepressant and a benzodiazepine, particularly for patients with severe panic symptoms. This approach provides the rapid anxiolysis of the benzodiazepine, while waiting for the antidepressant to “kick in.” When symptoms are adequately controlled, the benzodiazepine can be gradually tapered and discontinued, and most patients can continue taking an antidepressant as monotherapy. Occasionally, patients may need benzodiazepines on an “as needed” basis for breakthrough panic symptoms.

Other agents

Many other agents have also been reported effective against panic disorder, including venlafaxine, nefazodone, monoamine oxidase (MAO) inhibitors, and carbamazepine.³⁴⁻³⁷ At present these medications are not first- or second-line agents and may be more suitable for use by a psychiatrist or other physician who is familiar with their use in panic disorder. Oftentimes these medications, particularly the MAO inhibitors, are reserved for treatment-resistant panic or for patients who cannot take SSRIs, tricyclic antidepressants, or benzodiazepines for whatever reason.

REFERENCES

1. Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. *Am J Psychiatry* 1994; 151:413-420.
2. Katon WJ. Panic disorder in the medical setting: US Department of Health and Human Services Publication ADM 89-1629. Washington, D.C., US Government Printing Office, 1989.
3. Shear MK, Schulberg HC. Anxiety disorders in primary care. *Bull Menninger Clin* 1995; 59(2, Suppl A):A73-A85.
4. Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. *J Clin Psychiatry* 1996; 57(Suppl 10):11-18.
5. Salvador-Carulla L, Segui J, Fernandez-Cano P, Canet J. Costs and offset effect in panic disorders. *Br J Psychiatry* 1995; 166(Suppl 2):23-28.
6. Klerman GL. Treatments for panic disorder. *J Clin Psychiatry* 1992; 53(Suppl 3):14-19.
7. Simon GE, Von Korff M. Somatization and psychiatric disorder in the Epidemiologic Catchment Area study. *Am J*



- Psychiatry 1991; 148:1494-1500.
8. **Keller MB, Hanks DL.** Course and outcome in panic disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 1993; 17:551-570.
 9. **Lepine JP, Chignon JM, Teherani M.** Suicide attempts in patients with panic disorder. *Arch Gen Psychiatry* 1993; 50:144-149.
 10. **American Psychiatric Association.** Diagnostic and statistical manual of mental disorders, 4th ed. Washington, D.C.: American Psychiatric Association, 1994.
 11. **Skerret PW.** Anxiety and the heart: a historical review. *Psychol Med* 1983; 13:17-25.
 12. **Fleet RP, Dupuis G, Marchand A, et al.** Panic disorder in emergency department chest pain patients: prevalence, comorbidity, suicidal ideation, and physician recognition. *Am J Med* 1996; 101:371-380.
 13. **Mukerji V, Beitman BD, Alpert MA.** Chest pain and angiographically normal coronary arteries: implications for treatment. *Tex Heart Inst J* 1993; 20:170-179.
 14. **Katon W, Hall ML, Russo J, et al.** Chest pain: relationship of psychiatric illness to coronary arteriographic results. *Am J Med* 1988; 84:1-9.
 15. **Fogarty J, Engel CC, Russo J, et al.** Hypertension and pheochromocytoma testing: the association with anxiety disorders. *Arch Fam Med* 1994; 3:55-60.
 16. **Katon W.** Primary care: psychiatry panic disorder management module. In: Wolfe BE, Maser JD, editors. *Treatment of panic disorder: a consensus development conference.* Washington, D.C.: American Psychiatric Press, 1994.
 17. **Stewart WF, Shechter A, Liberman J.** Physician consultation for headache pain and history of panic: results from a population-based study. *Am J Med* 1992; 92(Suppl A):S35-S40.
 18. **Walker EA, Roy-Byrne PP, Katon WJ.** Irritable bowel syndrome and psychiatric illness. *Am J Psychiatry* 1990; 147:565-572.
 19. **Walker EA, Gelfand AN, Gelfand MD, Katon WJ.** Psychiatric diagnoses, sexual and physical victimization, and functional disability in patients with irritable bowel syndrome or inflammatory bowel disease. *Psychol Med* 1995; 25:1259-1267.
 20. **Crowe RR.** The genetics of panic disorder and agoraphobia. *Psychiatr Dev* 1985; 2:171-186.
 21. **Torgerson S.** Genetic factors in anxiety disorders. *Arch Gen Psychiatry* 1983; 40:1085-1089.
 22. **Rosenbaum JF, Biederman J, Gersten M, et al.** Behavioral inhibition in children of parents with panic disorder and agoraphobia. *Arch Gen Psychiatry* 1988; 45:463-470.
 23. **Silove D, Harris M, Morgan A, et al.** Is early separation anxiety a specific precursor of panic disorder-agoraphobia? A community study. *Psychol Med* 1995; 25:405-411.
 24. **Rosenbaum JF, Pollock R, Otto MW, Pollack MH.** Integrated treatment of panic disorder. *Bull Menninger Clin* 1995; 59:5-26.
 25. **Bruce TJ, Spiegel DA, Gregg SF, Nuzzarello A.** Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder. *Am J Psychiatry* 1995; 152:1156-1160.
 26. **Schneier FR, Liebowitz MR, Davies SO.** Fluoxetine in panic disorder. *J Clin Psychopharm* 1990; 10:119-121.
 27. **Gorman J, Wolkow R.** Sertraline as a treatment for panic disorder. *Neuropsychopharmacology* 1994; 10:355-375.
 28. **Oehrberg S, Christiansen PE, Behnke K, et al.** Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. *Br J Psychiatry* 1995; 167:374-379.
 29. **Black DW, Wesner R, Bowers W, Gabel J.** A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. *Arch Gen Psychiatry* 1993; 50:44-50.
 30. **Bradwejn J.** Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions. *Can J Psychiatry* 1993; 38(Suppl 4):S109-S113.
 31. **Noyes R Jr, Burrows GD, Reich JH, et al.** Diazepam versus alprazolam for the treatment of panic disorder. *J Clin Psychiatry* 1996; 57:349-355.
 32. **Lydiard RB, Laraia MT, Ballenger JC, Howell EF.** Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. *Am J Psychiatry* 1987; 144:664-665.
 33. **Mavissakalian MR, Perel JM.** Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. *Am J Psychiatry* 1995; 152:673-682.
 34. **Geraciotti TD.** Venlafaxine treatment of panic disorder: a case series. *J Clin Psychiatry* 1995; 56:408-410.
 35. **DeMartinis NA, Schweizer E, Rickels K.** An open-label trial of nefazodone in high comorbidity panic disorder. *J Clin Psychiatry* 1996; 57:245-248.
 36. **Van Vliet I, Westenberg H, DenBoer J.** The efficacy of a reversible MAO inhibitor, brofaromine, in panic disorder. *Biol Psychiatry* 1991; 29(Suppl):2665-2675.
 37. **Tondo L, Burrai C, Scamonatti L, et al.** Carbamazepine in panic disorder (letter). *Am J Psychiatry* 1989; 146:558-559.

ADDRESS: David J. Muzina, MD, Fairview Lutheran Hospital, 2609 Franklin Boulevard, Cleveland, OH 44113.

THE CLEVELAND CLINIC
FOUNDATION



Intensive Review of Internal Medicine

Video Cassette Library
Audio Cassette Library
Interactive CD-ROM

**Board Oriented
Board Simulation Sessions**

4 EASY WAYS TO ORDER

Telephone: 216/444-8420 or 800-238-6750 • Fax: 216-444-8410
Mail to: Unitech Communications, 9500 Euclid Ave., Ab2, Cleve., Ohio 44195
Web address: <http://www.ccfunitech.com>

UNITECH COMMUNICATIONS IS A SUBSIDIARY OF THE CLEVELAND CLINIC FOUNDATION